BEAM
Companies
NASDAQ
Beam Therapeutics Inc.
Health Care
$16.67
-$7.81 (-31.49%)
Price Chart
Overview
About BEAM
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Market Cap
$1.9B
Volume
50.3M
Avg. Volume
42.0M
P/E Ratio
-3.104822
Dividend Yield
0.00%
Employees
504.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.56
High Correlation
Volatility
High (0.70)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BEAM shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.9B
Volume50.3M
P/E Ratio-3.10
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 25, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025